Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Qingxiao Chen, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Jing Chen, Xiaoyan Han, Li Yang, Wenjun Wu, YI LI, Donghua He, Jingsong He, Zhen Cai

Blood (2024) 144 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2024-197887

Published: 2024

Journal Articles

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Shuchan Li, Xiaoyan Han, Gaofeng Zheng, Jingsong He, Wenjun Wu, Yang Yang, Qingxiao Chen, Donghua He, Mengmeng Dong, Jinuo Wang, Yi Li, Li Yang, Zhen Cai

Blood (2023) 142 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2023-184617

Published: 2023

Journal Articles

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Wenjun Wu, Yi Zhao, Yi Li, Zhen Cai

Blood (2023) 142 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2023-184794

Published: 2023

Journal Articles

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Donghua He, Xinyi Meng, Jingsong He, Wenjun Wu, Jinuo Wang, Chunting Zhu, Xiaoyan Han, Yi Zhao, Gaofeng Zheng, Yi Li, Xing Guo, Qingxiao Chen, Fangshu Guan, Zhen Cai

Blood (2023) 142 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2023-184689

Published: 2023

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients

Mengmeng Dong, Jinna Zhang, Qingxiao Chen, Honghua He, Haimeng Yan, Gaofeng Zheng, Xiaoyan Han, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2022-156536

Published: 2022

Journal Articles

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

XiaoYan Yue, GaoFeng Zheng, Donghua He, Yang Yang, Xiaoyan Han, Yi LI, Yi Zhao, Qingxiao Chen, WenJun Wu, He Huang, Zhen Cai, Jingsong He

Blood (2022) 140 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2022-159859

Published: 2022

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

ALKBH5 Functions As an Oncogene in Multiple Myeloma

Jianwei Qu, Yifan Hou, Qingxiao Chen, Jing Chen, YI LI, Enfan Zhang, Huiyao Gu, Ruyi Xu, Yang Liu, Jingsong He, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2021-149622

Published: 2021

Journal Articles

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Jingsong He, MD, Qingxiao Chen, MS, Yang Yang, MD, Yi Li, MD, Li Yang, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 5392.

https://doi.org/10.1182/blood.V130.Suppl_1.5392.5392

Published: 2017

Journal Articles

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Qingxiao Chen, MS, Jingsong He, MD, Huiyao Gu, Xi Huang, MD, Jing Chen, MD, Zhang En Fan, Xing Guo, MD, Haimeng Yan, He Huang, MD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 3079.

https://doi.org/10.1182/blood.V130.Suppl_1.3079.3079

Published: 2017

Journal Articles

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway

Xi Huang, Zhang En Fan, Qingxiao Chen, MS, Haimeng Yan, Xu Ruyi, Xinling Liu, Huiyao Gu, Jingsong He, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 1787.

https://doi.org/10.1182/blood.V130.Suppl_1.1787.1787

Published: 2017

Journal Articles

Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma

Jing Chen, M.MD, Donghua He, PhD, Xing Guo, M.MD, Qingxiao Chen, M.MD, Xuanru Lin, M.MD, Jingsong He, Xi Huang, M.MD, Haimeng Yan, Yi Li, PhD, Li Yang, PhD, Yang Yang, PhD, Enfan Zhang, M.MD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 4429.

https://doi.org/10.1182/blood.V128.22.4429.4429

Published: 2016

Journal Articles

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Xing Guo, M.MD, Donghua He, PhD, Jing Chen, M.MD, Xuanru Lin, M.MD, Qingxiao Chen, M.MD, Haimeng Yan, Xi Huang, M.MD, Yi Li, PhD, Li Yang, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, Wenjun Wu, MD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 2086.

https://doi.org/10.1182/blood.V128.22.2086.2086

Published: 2016

Journal Articles

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib

Xi Huang, M.MD, Enfan Zhang, M.MD, Xing Guo, M.MD, Jing Chen, M.MD, Xuanru Lin, M.MD, Qingxiao Chen, M.MD, Haimeng Yan, Li Yang, PhD, Yi Li, PhD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 2068.

https://doi.org/10.1182/blood.V128.22.2068.2068

Published: 2016

Journal Articles

TET2 Downregulation Promotes AML Cell Proliferation Via Pim-1 Expression

Qingxiao Chen, M.MD, Jingsong He, Xing Guo, M.MD, Jing Chen, M.MD, Xuanru Lin, M.MD, Xi Huang, M.MD, Haimeng Yan, Li Yang, PhD, Yi Li, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 5085.

https://doi.org/10.1182/blood.V128.22.5085.5085

Published: 2016

Journal Articles

Interleukin-32 Induce Production of IL-6 in Multiple Myeloma Bone Marrow Stromal Cells

Xuanru Lin, M.MD, Xing Guo, M.MD, Jing Chen, M.MD, Qingxiao Chen, M.MD, Enfan Zhang, M.MD, Yi Li, PhD, Li Yang, PhD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 3253.

https://doi.org/10.1182/blood.V128.22.3253.3253

Published: 2016

Journal Articles

Quercetin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in Vitro and In Vivo Xenograft Models

Xing Guo, M.MD, Donghua He, PhD, Li Yang, PhD, Yi Li, PhD, Qingxiao Chen, M.MD, Jing Chen, M.MD, Enfan Zhang, M.MD, Xuanru Lin, M.MD, Jingsong He, PhD, Yang Yang, PhD, Xiaoyan Han, MD, Gaofeng Zheng, MD, Wenjun Wu, MD, Yi Zhao, PhD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2015) 126 (23): 5339.

https://doi.org/10.1182/blood.V126.23.5339.5339

Published: 2015

Journal Articles

TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

Qingxiao Chen, M.MD, Jingsong He, PhD, Xing Guo, M.MD, Jing Chen, M.MD, Li Yang, PhD, Xuanru Lin, M.MD, Yi Li, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, Wenjun Wu, MD, Donghua He, PhD, He Huang, MD PhD, Shizhou Liu, MD PhD, Zhen Cai, MD PhD

Blood (2015) 126 (23): 3643.

https://doi.org/10.1182/blood.V126.23.3643.3643

Published: 2015

Journal Articles

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

Jing Chen, M.MD, Donghua He, PhD, Xing Guo, M.MD, Li Yang, M.MD, Yi Li, M.MD, Qingxiao Chen, M.MD, Jingsong He, Yang Yang, PhD, Enfan Zhang, M.MD, WenJun Wu, Xiaoyan Han, M.MD, Gaofeng Zheng, M.MD, Yi Zhao, PhD, He Huang, MDPhD, Zhen Cai, MDPhD

Blood (2014) 124 (21): 5701.

https://doi.org/10.1182/blood.V124.21.5701.5701

Published: 2014

NARROW

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

ALKBH5 Functions As an Oncogene in Multiple Myeloma

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway

Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib

TET2 Downregulation Promotes AML Cell Proliferation Via Pim-1 Expression

Interleukin-32 Induce Production of IL-6 in Multiple Myeloma Bone Marrow Stromal Cells

Quercetin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in Vitro and In Vivo Xenograft Models

TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only